View More Recent Stories
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
GeneDx Holdings (WGS) 6900 contracts trade compared to 90-day average of 442 contracts as share price up 38%
-
GeneDx Holdings (WGS) Reports Q4 results; offers guidance
-
GeneDx Holdings (WGS) Announces ultraRapid Whole Genome Sequencing
-
GeneDx Integrates with Epic through launch on Aura
-
Craig-Hallum on GeneDx Holdings (WGS): 'Would Buy on Weakness' (Tuesday)
-
Jefferies Reiterates Hold Rating on GeneDx (WGS)
-
BTIG Defending GeneDx (WGS)
-
Grizzly Research is short GeneDx Holdings (WGS)
-
GeneDx (WGS) Announces Preliminary 2024 Financial Results
-
GeneDx (WGS) PT Raised to $118 at TD Cowen, Citing 'Strong Competitive Position'
-
GeneDx Holdings (WGS) Appoints Bryan Dechairo as COO
-
GeneDx Holdings (WGS) Misses Q3 EPS by 31c
-
GeneDx Holdings (WGS) December 85 calls active as share price up 44%
-
GeneDx (WGS) PT Raised to $50 at TD Cowen
-
GeneDx (WGS) PT Raised to $45 at BTIG
-
GeneDx Holdings (WGS) Misses Q2 EPS by 46c; offers guidance
-
Craig-Hallum Starts GeneDx (WGS) at Buy
-
GeneDx (WGS) PT Raised to $35 at BTIG

